Updated:
Biosensors International Group
Singapore-based Biosensors International Group builds its interventional cardiology portfolio around the Biolimus A9 drug-eluting stent platform.
Biosensors International Group
Biosensors International Group maintains its primary footprint in Singapore, with additional offices in Bengaluru and Mumbai. The firm’s product architecture centers on a single proprietary anti-proliferative agent, Biolimus A9, deployed across multiple stent and balloon platforms. Its clinical program supports frontline interventional tools including the BioFreedom Ultra polymer-free drug-eluting stent and the BioMatrix Alpha stent, which bundles Biolimus A9 with a biodegradable polymer. The Allegra transfemoral and transapical TAVI system extends the portfolio into structural heart. The firm distributes directly and through partners into the US, French, and broader Asian markets. The device portfolio spans coronary and peripheral intervention, anchored by drug-eluting stent and balloon catheter families. BioFreedom Ultra and BioFreedom target high-bleeding-risk patients with a polymer-free carrier that achieves comparable late lumen loss to polymer-coated competitors. BioMatrix Alpha combines that same limus agent with a bioabsorbable polymer aimed at lowering long-term thrombotic risk. The balloon range covers non-compliant (Rise NC) and semi-compliant (Rise SC) post-dilatation catheters, along with the Biomc microcatheter for tortuous anatomy. The Allegra TAVI valve rounds out the offering with a self-expanding nitinol frame for aortic stenosis, sold in Europe and select Asian markets. Operations span three named offices across Singapore, Bengaluru, and Mumbai. The firm lists separate digital fronts for its US (biosensors.com/us) and French (biosensors.com/fr) commercial units, suggesting direct sales infrastructure in those regions alongside its broader Asia-based distribution. No public team-size figure or deployment level is disclosed. The website provides an ethics hotline and standard privacy and cookie-notice infrastructure, with no named executives or board members surfaced on the scraped corporate homepage. Structurally, Biosensors International operates as a specialized medtech play rather than a broad life-sciences fund or multi-asset family office. Its entire clinical program orbits a single molecule, which concentrates platform risk but also concentrates clinical data, regulatory familiarity, and supply-chain simplicity. The firm does not publicly disclose whether it runs a formal fund vehicle, invests off a balance sheet, or accepts outside co-investment. No recent operational announcements, fundraising rounds, or personnel changes are verifiable from the available source material.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
Singapore
City
Singapore
Corporate office
Singapore
Additional offices
Bengaluru · Mumbai
Sector focus
Frequently asked questions
What is Biosensors International Group's core technology platform?
The firm builds its entire interventional cardiology portfolio around Biolimus A9, a proprietary anti-proliferative agent derived from sirolimus. This single compound appears across the BioFreedom, BioMatrix, and Allegra product families. The polymer-free BioFreedom platform targets high-bleeding-risk patients, while BioMatrix Alpha pairs the same drug with a bioabsorbable polymer.
Does Biosensors operate as a fund or an operating company?
The available public materials present Biosensors International as a medical-device operating company with a direct commercial footprint, not as a pooled investment fund. Its website lists products, clinical programs, and geographic sales offices in the US and France. No fund structure, investor portal, or fundraising activity is disclosed on the scraped homepage or broader site.
Which markets does Biosensors serve directly?
The firm maintains separate web presences for its US and French subsidiaries, suggesting direct sales operations in those countries. Physical offices are confirmed in Singapore, Bengaluru, and Mumbai. The Allegra TAVI system is marketed in Europe and select Asian countries, indicating a wider regional distribution network beyond the three named office locations.
What clinical differentiator does BioFreedom claim relative to polymer-coated stents?
BioFreedom Ultra uses a micro-structured abluminal surface to deliver Biolimus A9 without a polymer carrier. In the LEADERS FREE trial program, the platform demonstrated superior safety versus bare-metal stents in high-bleeding-risk patients treated with one month of dual antiplatelet therapy. The absence of polymer eliminates a potential trigger for chronic inflammation and late stent thrombosis.
Who runs investment and strategy decisions at Biosensors International?
No named principals, executives, or board members are publicly surfaced on the firm's corporate website or in the available Altss research record. The organization's governance structure and investment decision-making process remain opaque to external observers without deeper primary sourcing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: